NYSE: IQV · Diagnostics & Research
IQVIA Holdings (IQV) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values IQVIA Holdings (IQV) at $335.69 a share. The stock last closed at $264.73, which puts the model's fair value 26.8% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. IQVIA Holdings Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $349.11 to $335.69 (-3.8%). Analysts cut their next-twelve-month EBITDA estimates: most of the move.
What the model makes of itThe price of $264.73 is 26.8% below it: Undervalued, on a high evidence grade.
What's nextNext report on 4 Feb 2027. Options prices imply a move of about 11% either way over the next month. On the model's Scorecard Leaders list since 29 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give IQV?
The calibrated range for IQV over 63 trading days is $232.99 to $302.74. It sits around the last close, and its width comes from the volatility that IQV's own options imply (39% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $270.84 to $406.77. In 83% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
IQVIA Holdings Inc. (IQV) is a premier global provider of sophisticated analytical insights, advanced technology solutions and comprehensive clinical research services. It serves the life sciences industry across the Americas, Europe, Africa and Asia-Pacific.
Faircurve's model put the fair value at $335.69 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $349.11, so the fair value moved -3.8%. The model's own reason is that analysts cut their next-twelve-month EBITDA estimates, which is most of the move. The calibrated range over 63 trading days is $234.15 to $302.07. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. The grade covers input completeness, the number and agreement of comparable companies, and the spread of outcomes. It does not say whether the fair value is right.
The model's overall quality score for IQVIA is 55 out of 100, a composite of six factors scored against comparable companies. Three stand out. Balance sheet scores 18, with net debt to EBITDA of 3.91x against a peer median of 1.91x. Earnings quality scores 69, with FCF to net income of 1.49x against a peer median of 1.10x. Stability scores 64, with five-year EBITDA margin downside volatility of 1.1 pts against a peer median of 1.8 pts. The model compares IQVIA with Waters, Agilent, Mettler-Toledo, IDEXX, Illumina, Quest Diagnostics and Medpace.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does IQV report earnings, and how has the stock reacted?
IQVIA Holdings's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 9.0% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. IQV's 30 day implied volatility works out to about 11.2% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across IQV's last 8 reports, ignoring direction, was 4.8%.
What the options market has priced for a month's move in IQV
How does IQV score on business quality?
IQVIA Holdings's overall quality score is 55 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 55 | 9.4%ROIC | 9.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 69 | 1.49xFCF / net income | 1.10x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 60 | 5.9%Revenue growth, trailing | 3.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 50 | 2.7%Net buybacks / market value | 2.2% |
| Balance sheetNet debt to EBITDA and interest coverage. | 18 | 3.91xNet debt / EBITDA | 1.91x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 64 | 1.1 ptsEBITDA margin downside volatility, 5y | 1.8 pts |
How does IQV compare with similar companies?
The companies in diagnostics & research closest to IQVIA Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| WAT Waters Corporation | $453.42 | $337.75 | -25.5% | Overvalued |
| A Agilent Technologies, Inc. | $172.92 | $176.09 | +1.8% | Fairly valued |
| MTD Mettler-Toledo International Inc. | $1,727.26 | $1,679.36 | -2.8% | Fairly valued |
| IDXX IDEXX Laboratories, Inc. | $700.65 | $568.18 | -18.9% | Overvalued |
| ILMN Illumina, Inc. | $198.00 | $172.96 | -12.6% | Fairly valued |
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
| DGX Quest Diagnostics Incorporated | $262.21 | $314.32 | +19.9% | Undervalued |
| MEDP Medpace Holdings, Inc. | $648.20 | $717.73 | +10.7% | Fairly valued |
What the comparable companies' multiples alone would give for IQV, the peer-implied price, is $410.32 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
IQVIA Holdings at a glance
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific.
- Market value
- $43.7B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $18.4B
- Consensus revenue growth, next fiscal year
- +7.2%
- Analysts with estimates
- 13
- Beta to the US market
- 0.64
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. IQV was among them.
How the fair value is worked out: the model prices IQVIA Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for IQV was $349.11. As of 14 Nov 2026 it is $335.69, a change of -3.8%. Analysts cut their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about IQVIA Holdings's valuation
Is IQVIA Holdings stock undervalued or overvalued?
On Faircurve's model, IQV reads as Undervalued as of 14 Nov 2026. The model's fair value is $335.69 a share against a last close of $264.73, a gap of +26.8%.
What is IQV's fair value?
$335.69 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $270.84 to $406.77.
What price range does the model give IQV?
$232.99 to $302.74 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does IQVIA Holdings report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has IQV moved on past earnings reports?
Across its last 8 reports the median two session move was 4.8%, ignoring direction. The largest was +22.2% around the report of 22 Jul 2025.
How confident is the model in this valuation?
The model's evidence grade for IQV is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on IQV
The model has an idea open on IQV under Scorecard Leaders since 29 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on IQV with their outcomes. A free account is enough.